Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical haematopoietic SCT

Schwarer, Anthony P.; Bollard, G M; Kapuscinski, Miroslav; Muirhead, Jenny; Diviney, Mary; Hart, Christina; Dunster, K

doi:10.1038/bmt.2010.299

Cited by 5 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The NRM in our study was also higher than described in other publications about haploidentical transplantations using PTCY [18,19,26], but in those studies patients were younger and were mostly in complete remission. NRM found in our study was comparable with studies on haploidentical HCT with in vivo T-cell depleted grafts [27][28][29].…”

Section: Discussionsupporting

confidence: 90%

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Gorkom¹,

Gelder²,

Eikema

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.

show abstract

Section: Discussionsupporting

confidence: 90%

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Gorkom¹,

Gelder²,

Eikema

et al. 2017

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Various other groups have confirmed the feasibility and low toxicity of this RIC for allogeneic HSCT. [30][31][32][33] Consequently, the median age of the CD3/19 patients reported here is approximately a decade older than that previously reported in adult patients receiving haplo-HSCT with CD34 selected grafts. 5,34 The significant influence of graft composition and conditioning regimen on engraftment is illustrated by the fast engraftment kinetics observed.…”

Section: Discussionmentioning

confidence: 40%

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study

Bornhäuser²,

et al. 2012

View full text Add to dashboard Cite

BackgroundWe report a prospective multicenter phase II study of haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3. Design and MethodsSixty-one adults with a median age of 46 years (range 19-65 years) have been enrolled. Diagnoses were acute myeloid leukemia (n=38), acute lymphoblastic leukemia (n=8), nonHodgkin's lymphoma (n=6), myeloma (n=4), chronic myeloid leukemia (n=3), chronic lymphatic leukemia (n=1) and myelodysplastic syndrome (n=1). Patients were considered high risk because of refractory disease (n=18), cytogenetics (n=6), complete remission (≥2) (n=9), chemosensitive relapse in partial remission (n=4) or relapse after prior hematopoietic stem cell transplantation (n=15 allogeneic, n=8 autologous, n=1 both). At haploidentical hematopoietic stem cell transplantation, 30 patients were in complete remission and 31 in partial remission. Grafts contained a median of 7.0×10 6 (range 3. ResultsEngraftment was rapid with a median of 12 days to granulocytes more than 0.5×10 9 /L (range 9-50 days) and 11 days to platelets more than 20×10 9 (range 7-38 days). Incidence of grade II-IV acute graft-versus-host-disease and chronic graft-versus-host-disease was 46% and 18%, respectively. Non-relapse mortality on Day 100 was 23% and 42% at two years. Cumulative incidence of relapse/progression at two years was 31%. Kaplan-Meier estimated 1-year and 2-year overall survival with median follow up of 869 days (range 181-1932) is 41% and 28%, respectively. ConclusionsThis regimen allows successful haploidentical hematopoietic stem cell transplantation with reduced intensity conditioning in high-risk patients lacking a suitable donor. (clinicaltrials.gov identifier:NCT00202917).

show abstract

“…We, and others performed this type of TCD haploidentical HSCT in the past and were not able to duplicate the results from Perugia. We observed an even higher rate of NRM and accordingly extremely low survival rates and have abandoned this type of transplantation [ 4 , 5 ]. Interesting strategies have been developed to overcome this drawback of TCD haploidentical HSCT, for instance by only removing specific cell types in vitro [ 6 , 7 ].…”

Section: Introductionmentioning

confidence: 99%

Real‐world experience: Introduction of T cell replete haploidentical transplantations in a single center

Gorkom

Billen

Elssen

et al. 2021

eJHaem

View full text Add to dashboard Cite

Objectives The aim of this study was to describe real‐world data on outcomes of T cell replete haploidentical hematopoietic stem cell transplantation (HSCT) after the introduction of this modality in a single center and to compare them with different donor types. Method Outcomes of 30 consecutive patients with hematological malignancies that received T cell replete haploidentical HSCT with posttransplantation cyclophosphamide (PTCY) from 2016 to 2018 in our center were analyzed and compared to the outcome of human leukocyte antigen (HLA)‐related and unrelated matched donor HSCT (n = 97) and to a historical cohort of T cell depleted haploidentical HSCT (n = 11). Results One year graft‐versus‐host‐free, relapse‐free survival in haploidentical HSCT was comparable with other donor types (haplo 40%, matched related donor [MRD] 33%, matched unrelated donor [MUD] 25%, p = 0.55). Non relapse mortality was high in haploidentical HSCT (50%), mostly due to infectious complications. However, relapse rates were only 3%, and OS and progression‐free survival after 1 year were 47% and thereby also similar to HLA‐matched HSCT in our center (MRD 53%, MUD 48%). Conclusion Our data show that T cell replete haploidentical HSCT has similar outcomes to HLA identical HSCT after introduction in our center. More strict adaptation on infection prevention was a crucial aspect of our learning curve. Overall, this type of transplantation is a feasible option when lacking an HLA‐identical donor. This option has advantages over an unrelated donor as it brings less logistical challenges than MUD transplantations.

show abstract

Long-term follow-up of a pilot study using a chemotherapy-alone protocol for killer Ig-like receptor-ligand-mismatched haploidentical haematopoietic SCT

Cited by 5 publications

References 43 publications

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT

Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: a phase II study

Real‐world experience: Introduction of T cell replete haploidentical transplantations in a single center

Contact Info

Product

Resources

About